Albireo Debt to Equity

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Albireo Pharma Debt to Equity Ratio is very stable at the moment as compared to the past year. Albireo Pharma reported last year Debt to Equity Ratio of 0.83. As of 22nd of March 2023, Average Equity is likely to grow to about 191.9 M, while Long Term Debt to Equity is likely to drop 0.05.

Receivables Inventories

Albireo Debt to Equity Analysis

Albireo Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

	2020	2021	2022	2023 (projected)
Revenues USD	8.31 M	40.58 M	46.67 M	50.35 M
Revenues	8.31 M	40.58 M	46.67 M	50.35 M

Revenues USD Revenues

D/E

Total Debt

Total Equity

More About Debt to Equity | All Equity Analysis

Current Albireo Pharma Debt to Equity

0.18 %

Most of Albireo Pharma's fundamental indicators, such as Debt to Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Albireo Debt to Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Albireo Pharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Debt to Equity. Since Albireo Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Albireo Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Albireo Pharma's interrelated accounts and indicators.

Albireo Debt to Equity Historical Pattern

Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Albireo Pharma debt to equity as a starting point in their analysis.

Albireo Pharma Debt to Equity

Timeline

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Albireo Shareholders Equity

Shareholders Equity

217.89 Million

Albireo Pharma Shareholders Equity is very stable at the moment as compared to the past year. Albireo Pharma reported last year Shareholders Equity of 201.95 Million

According to the company disclosure, Albireo Pharma has a Debt to Equity of 0.179%. This is 99.67% lower than that of the Biotechnology sector and 99.08% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.63% higher than that of the company.

Albireo Debt to Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Debt to Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.

Albireo Pharma is currently under evaluation in debt to equity category among related companies.

Albireo Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.

	2018	2019	2020	2021	2022	2023 (projected)
Net Income Per Employee	(1.18 M)	(1.14 M)	(1.19 M)	(261.77 K)	(301.03 K)	(324.8 K)
Revenue Per Employee	326.67 K	175.2 K	92.06 K	312.15 K	358.97 K	360.48 K
Average Assets	199.19 M	172.87 M	240.71 M	266.95 M	307 M	331.23 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	(41.21 M)	(57.29 M)	(96.08 M)	(19.82 M)	(17.84 M)	(19.25 M)
Earnings Before Interest Taxes and Depreciation Amortization USD	(41.21 M)	(57.29 M)	(96.08 M)	(19.82 M)	(17.84 M)	(19.25 M)
Earnings before Tax	(46.09 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Average Equity	142.23 M	105.98 M	148.89 M	154.69 M	177.89 M	191.93 M
Enterprise Value	120.02 M	179.83 M	446.4 M	196.32 M	225.76 M	188.69 M
Free Cash Flow	(26.85 M)	(53.46 M)	(101.11 M)	(108.02 M)	(97.22 M)	(99.78 M)
Invested Capital	(8.5 M)	(2.96 M)	1.41 M	1.34 M	1.54 M	1.66 M
Invested Capital Average	(5.73 M)	(3.27 M)	2.73 M	(872 K)	(784.8 K)	(846.76 K)
Market Capitalization	293.62 M	322.49 M	715.59 M	449 M	516.35 M	557.11 M
Tangible Asset Value	168.21 M	147.81 M	268.35 M	284.79 M	327.51 M	353.37 M
Working Capital	154.82 M	122.88 M	236.58 M	223.58 M	257.12 M	277.42 M

Albireo Fundamentals

	Return On Equity	(0.93) %
	Return On Asset	(0.25) %
	Profit Margin	(2.29) %
	Operating Margin	(2.15) %
	Current Valuation	259.98 M
	Shares Outstanding	20.74 M
	Shares Owned by Insiders	3.60 %
	Shares Owned by Institutions	96.40 %
	Number of Shares Shorted	553.91 K
	Price to Earning	(4.16) X
	Price to Book	4.30 X
	Price to Sales	7.35 X
	Revenue	40.58 M
	Gross Profit	39.22 M
	EBITDA	(19.82 M)
	Net Income	(34.03 M)
	Cash and Equivalents	180.97 M
	Cash per Share	9.23 X
	Total Debt	10 M
	Debt to Equity	0.18 %
	Current Ratio	4.49 X
	Book Value Per Share	4.84 X
	Cash Flow from Operations	(107.56 M)
	Short Ratio	0.86 X
	Earnings Per Share	(6.66) X
	Target Price	44.0
	Number of Employees	130
	Beta	1.04
	Market Capitalization	915.89 M
	Total Asset	302.05 M
	Retained Earnings	(171.75 M)
	Working Capital	26.76 M
	Current Asset	28.84 M
	Current Liabilities	2.07 M
	Z Score	54.6
	Net Asset	302.05 M

About Albireo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

	Last Reported	Projected for 2023
Long Term Debt to Equity	0.05	0.05
Debt to Equity Ratio	0.83	0.89
Average Equity	177.9 M	191.9 M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.87	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.71	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.59	AADI	Aadi Bioscience	Earnings Call This Week	Pair Corr
-	0.54	ACGN	Aceragen	Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Probability Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Global Correlations Find global opportunities by holding instruments from different markets
	Commodity Channel Index Use Commodity Channel Index to analyze current equity momentum
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

	Accounts Payable	Total Assets	Current Assets	Cash and Equivalents	Total Debt	Debt Current	Shareholders Equity	Total Liabilities	Current Liabilities	Tax Assets	Tax Liabilities
Accounts Payable		0.96	0.96	0.96	0.74	0.82	0.95	0.95	0.87	-0.28	-0.35
Total Assets	0.96		1.0	1.0	0.74	0.86	0.99	0.98	0.94	-0.32	-0.41
Current Assets	0.96	1.0		1.0	0.75	0.84	0.99	0.98	0.93	-0.3	-0.4
Cash and Equivalents	0.96	1.0	1.0		0.75	0.84	0.99	0.98	0.92	-0.3	-0.39
Total Debt	0.74	0.74	0.75	0.75		0.56	0.74	0.73	0.63	-0.22	-0.3
Debt Current	0.82	0.86	0.84	0.84	0.56		0.87	0.83	0.84	-0.44	-0.54
Shareholders Equity	0.95	0.99	0.99	0.99	0.74	0.87		0.96	0.9	-0.3	-0.39
Total Liabilities	0.95	0.98	0.98	0.98	0.73	0.83	0.96		0.96	-0.33	-0.43
Current Liabilities	0.87	0.94	0.93	0.92	0.63	0.84	0.9	0.96		-0.36	-0.47
Tax Assets	-0.28	-0.32	-0.3	-0.3	-0.22	-0.44	-0.3	-0.33	-0.36		0.98
Tax Liabilities	-0.35	-0.41	-0.4	-0.39	-0.3	-0.54	-0.39	-0.43	-0.47	0.98